ARS Pharmaceuticals Achieves FDA Approval for neffy® 1 mg
neffy 1 mg brings groundbreaking innovation as the first non-injection epinephrine treatment approved for young children.
The Need for a Needle-Free Solution
In the United States, food allergies affect a significant number of children, with about one in 13 kids suffering from life-threatening allergic reactions. Reports indicate over 40 percent of these children have faced severe allergic incidents. Unfortunately, many caregivers hesitate to administer epinephrine due to the common fear associated with needle-based injectors. The recent FDA approval of neffy® 1 mg (epinephrine nasal spray) marks a pivotal moment for effective treatment in children aged 4 and above weighing between 15 to less than 30 kilograms.
Why neffy® Matters
ARS Pharmaceuticals, Inc. has developed neffy, a nasal spray designed for emergency treatment of anaphylactic reactions, which provides a precise dosage without the use of needles. This efficient delivery method allows for rapid administration without the fear and anxiety that many parents and children associate with traditional injectors.
Expert Opinions on neffy®
Richard Lowenthal, Co-Founder and CEO of ARS Pharma, expressed his enthusiasm, stating, "The approval for neffy represents a substantial advancement in how children manage their severe allergies. Our goal is to eradicate fears about auto-injectors, which ultimately saves valuable time in emergencies." This perspective is echoed by leading healthcare professionals. Dr. David Fleischer, an allergy and immunology expert, emphasizes that the innovative design empowers families to act decisively in allergic emergencies.
The Impact of Clinical Trials
The approval of neffy was supported by extensive clinical trials demonstrating comparable pharmacokinetic and pharmacodynamic results to traditional epinephrine injectors. These trials ensured safety with minor side effects, reassuring both parents and healthcare providers about the efficacy and reliability of this new treatment.
Availability and Support Programs
ARS Pharmaceuticals plans to make neffy 1 mg available in the U.S. by the end of May 2025. Their neffyConnect program aims to assist families by providing essential information, financial support options, and guidance on navigating insurance. Most insured patients will only pay around $25 for a couple of doses through a co-pay savings initiative. For those without insurance, a cash price structure is available to ensure affordability.
In-School Access for Children
Schools taking part in the neffy inSchools program can obtain neffy 1 mg for their students. Such access ensures that children with allergies are adequately supported while in educational environments, showcasing ARS Pharma's commitment to safeguarding children everywhere.
Future of Allergy Management
This approval follows the recent endorsement of neffy 2 mg for slightly heavier children and adults, providing a full range of treatment options within this family of products. ARS Pharmaceuticals remains dedicated to addressing the vital need for reliable allergy treatments in both children and adults.
Commitment to Education and Safety
Further, ARS Pharmaceuticals emphasizes the importance of educating both patients and caregivers about administering neffy. The company advises always carrying two devices to ensure preparedness in case of re-emergence of symptoms after using the first dose. Understanding how to use the device promptly and effectively can significantly impact health outcomes in allergy emergencies.
Frequently Asked Questions
What is neffy® used for?
neffy® is an epinephrine nasal spray used for emergency treatment of allergic reactions, including anaphylaxis, in children aged 4 years and older.
How does neffy® work compared to traditional injectors?
neffy® delivers epinephrine through the nasal mucosa without needles, enabling quicker and more comfortable administration during allergic emergencies.
What are the expected side effects of neffy®?
Common side effects may include nasal discomfort, headache, and irritation. Serious side effects should be reported immediately to a healthcare provider.
When will neffy® be available?
The launch of neffy® 1 mg is anticipated in the U.S. by the end of May 2025.
Are there support programs for neffy®?
Yes, ARS Pharmaceuticals offers the neffyConnect program, which provides assistance with access, fulfillment, and financial guidance for patients and caregivers.
